Latest news

• EMA and ECDC publish advice on fourth doses of mRNA COVID-19 vaccines

  The fourth doses that were being considered are Pfizer’s Comirnaty and Moderna’s Spikevax – both mRNA COVID-19 vaccines.

• Pfizer expands access to lipid nanoparticle technology in new agreement with Acuitas Therapeutics

  Acuitas’ LNP technology is already used in the Pfizer/BioNTech COVID-19 vaccine, Comirnaty. ... Comirnaty. The Cominaty vaccine has since received full approval in the US and Canada, while it has received authorisation for emergency use in Europe, the

• South Africa releases first real-world evidence for Omicron

  Their analysis suggests that two doses of the Pfizer-BioNTech vaccine, Comirnaty, provides 70% protection against hospitalisation but only 33% protection from infection.

• Pfizer/BioNTech promote booster against Omicron

  Serum antibodies induced by the Pfizer/BioNTech COVID-19 vaccine (BNT162b2, Comirnaty) neutralise the Omicron variant of SARS-CoV-2 after three doses, suggest preliminary laboratory studies.

• Mix-and-match COVID-19 vaccines may be more effective

  substantial increase in antibody and T-cell responses’ but that the protection may be greater than a booster with Pfizer/BioNTech’s Comirnaty. ... However, with a J&J booster dose, antibodies continued to increase for at least four weeks whereas